Similar Search Results

The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: Evidence from longitudinal, disease-level data

Lichtenberg, Frank; Pettersson, Billie - 2012

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

Persistent link: https://www.econbiz.de/10010283600

Pharmaceutical Innovation, Mortality Reduction, and Economic Growth

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 1998

We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and … pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new … drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum. The drug innovation measures are …

Persistent link: https://www.econbiz.de/10005778568

The contribution of pharmaceutical innovation to longevity growth in Germany and France

Lichtenberg, Frank - 2010

I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I …-2006. The estimates imply that chemotherapy innovation accounted for at least one-sixth of the decline in French cancer …

Persistent link: https://www.econbiz.de/10010270528

Response to Baker and Fugh-Berman's critique of my paper, Why has longevity increased more in some states than in others?

Lichtenberg, Frank - 2009

increased more in some states than in others?" One of the conclusions I drew from that study was that medical innovation …-Berman express deep skepticism about my study's conclusion that medical innovation has played a very important role in recent U …

Persistent link: https://www.econbiz.de/10010272883

Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010

Lichtenberg, Frank - 2015

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months)- about 44% of the total increase in longevity -and … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

Persistent link: https://www.econbiz.de/10010480895

The Effect of New Drugs on Mortality from Rare Diseases and HIV

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2001

I investigate the effect of large increases in the number of drugs available to treat rare diseases and HIV on mortality associated with them. Mortality from both diseases declined dramatically following increases in drug approvals. Before the Orphan Drug Act went into effect (between 1979 and...

Persistent link: https://www.econbiz.de/10005720742

Sources of U.S. Longevity Increase, 1960-1997

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2002

models using annual U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual … data are available for only one type of innovation - new drugs - but pharmaceutical R&D accounts for a significant fraction … innovation (in the form of new drug approvals) and expenditure on medical care (especially public expenditure) contributed to …

Persistent link: https://www.econbiz.de/10005828594

The Output Contributions of Computer Equipment and Personnel: A Firm- Level Analysis

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 1993

This paper examines the output contributions of capital and labor deployed in information systems (IS) at the firm level during the period 1988-91 throughout the business sector, using two different sources of data on these inputs. Our production function estimates suggest that there are...

Persistent link: https://www.econbiz.de/10005828845

The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2002

We hypothesize that pharmaceutical-embodied technical progress increases per capita output via its effect on labor supply (the employment rate and hours worked per employed person). We examine the effect of changes in both the average quantity and average vintage (FDA approval year) of drugs...

Persistent link: https://www.econbiz.de/10005775072

The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2009

The rate of increase of longevity has varied considerably across U.S. states since 1991. This paper examines the effect of the quality of medical care, behavioral risk factors (obesity, smoking, and AIDS incidence), and other variables (education, income, and health insurance coverage) on life...

Persistent link: https://www.econbiz.de/10005660144